- Home
- CLPR vs ATYR Comparison
CLPR vs ATYR Comparison
Compare CLPR & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | ATYR |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | 58 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.3M | 46.1M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLPR | ATYR |
|---|---|---|
| Price | $3.11 | $0.57 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $3.67 |
| AVG Volume (30 Days) | 72.8K | ★ 2.0M |
| Earning Date | 05-14-2026 | 05-01-2026 |
| Dividend Yield | ★ 10.73% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $109,997,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.82 | N/A |
| 52 Week Low | $2.83 | $0.40 |
| 52 Week High | $4.61 | $7.29 |
Technical Indicators
Market Signals| Indicator | CLPR | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 46.97 | 55.96 |
| Support Level | $2.88 | $0.42 |
| Resistance Level | $3.28 | $0.59 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 25.81 | 89.48 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).